SPARCL1 and metabolic dysfunction-associated steatohepatitis: Therefore, the present study aimed to investigate the pharmacological activity and potential mechanism of Rosavin treatment on NASH management via targeting hepatic cell death-related (HSPD1/TNF/MMP14/ITGB1) mRNAs and their upstream noncoding RNA regulators (miRNA-6881-5P and lnc-SPARCL1-1:2) in NASH animal model.